Supplementary Table 3. Medication classes identified using Slone Drug Dictionary, NICHD Fetal GrowthStudies, Singletons (2009 -2013)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Medication Classes** | **% Overalla (n=2186)** | **% Women with Obesity (n=436)** | **% Women without Obesity (n=1750)** | **p-valueb** |
| Central Nervous System agents  | 47 | 50 | 46 | 0.11 |
| Gastrointestinal Drugs  | 41 | 43 | 40 | 0.33 |
| Anti-infective Agents  | 22 | 23 | 21 | 0.35 |
| Antihistamines  | 18 | 19 | 17 | 0.29 |
| Autonomic Drugs  | 10 | 10 | 9 | 0.50 |
| Hormones & Synthetic Substitutes  | 7 | 11 | 5 | <0.0001 |
| Respiratory Tract Agents  | 6 | 7 | 6 | 0.81 |
| Skin & Mucous Membrane Agents  | 3 | 3 | 3 | 0.85 |
| Unclassified -NOS  | 2 | 2 | 3 | 0.35 |
| EENT Preparations  | 1 | 0.9 | 1 | 0.76 |
| Cardiovascular Drugs  | 1 | 1.1 | 1 | 0.59 |
| Blood formation-Coagulation-Thrombosis  | 0.5 | 0.7 | 0.5 | 0.54 |
| Miscellaneous Therapeutic Agents  | 0.2 | 0.2 | 0.1 | 0.59 |
| Diagnostic Agents  | 0.2 | 0.2 | 0.2 | 0.59 |
| Local Anesthetics  | 0.14 | 0 | 0.2 | 1.0 |
| Blood Derivatives  | 0.05 | 0 | 0.06 | 1.0 |
| Antineoplastic Agents  | 0.05 | 0.2 | 0 | 0.20 |

Abbreviations: EENT, eye, ear, nose, and throat; NOS, not otherwise specified.

aPercent women were calculated by dividing the number of women who reported taking classes of medication by the total number of women in the study.

bP-values for bivariate comparisons, were obtained using X2 test of independence for the differences between women with and without obesity in each medication class.